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Improving patient flow of people with
rheumatoid arthritis has the potential to
simultaneously improve health outcomes
and reduce direct costs
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Abstract
Background: In our current economic climate of scarce resources there is a lot of debate around the best - and
most efficient - way of delivering care, which points patients towards the right physician at the earliest opportunity.
The aim of the study was to assess whether an improvement in the interdisciplinary management of rheumatoid
arthritis (RA) has the potential to simultaneously improve health outcomes and reduce costs.
Methods: In a first step, we modelled the ways which lead patients with RA to the correct diagnosis, and the
relevant specialist, respectively. On average, a patient experiences 3 GP visits before referral to a specialist. We
compared this situation against a reconfiguration of current practice towards a more proactive identification and
referral method with initiation of care by a rheumatologist early in the disease. We evaluated the impact of this
reconfiguration on the number of RA patients diagnosed and the costs associated with the diagnostic process.
Result: Using data on epidemiology and Austrian practice patterns, we estimate a total of 5294 people with
undifferentiated arthritis per year, of which 1765 suffer from RA. Modelling for diagnostic accuracy, we found that
1200 of these patients are initially misdiagnosed in a primary care setting and 95 at a rheumatologist. Our model
found that a reconfiguration of current practice towards an approach of more integrated care has the potential to
be not only cost-effective, but cost-saving: EUR 100,188 could be saved annually by exclusively adopting the new
approach.
Conclusions: Our results show that by better directing the flow of people with RA, simultaneous clinical and
economic benefits may be reaped:.
Keywords: Cost of illness, Delivery of care, Rheumatoid arthritis, Health care research
Background
Inflammatory rheumatic diseases occur frequently
across all age groups, job categories and social classes.
They cause frequent sick leave and occupational dis-
ability [1, 2]. Diseases such as rheumatoid arthritis
(RA) are characterized by their chronic and progressive
nature and may lead to premature loss of joint function.
Joint damage can occur early in the disease: after 2 years
about 75% of patients have already developed joint dam-
age with erosions [3, 4]. The need for early diagnosis and
prompt therapeutic measures is evident and beyond any
controversy nowadays, and an integral part of diagnostic
paths and therapeutic guidelines [4, 5].
In the last decade, due to a better understanding of the
pathogenesis of rheumatoid arthritis and its progression,
highly effective drugs have revolutionised treatment. Until
the end of the 1990s a reduction in the number of swollen
joints and a reduction of pain intensity was an accessible
and acceptable goal. Today, rheumatologists aim for
remission and a symptom free status respectively [4, 6].
In our current economic climate of scarce resources, it
has become mandatory to eliminate any potential for
duplication of diagnostic efforts. This has led to a lot of
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debate around the best - and most efficient - way of de-
livering care, which points patients towards the right
physician at the earliest opportunity. While this is the
order of the day for care in general, it is especially
important for people with inflammatory arthritis. Joint
destruction may happen early and progress rapidly.
Insufficient patient management at the primary care
level may lead to delayed diagnosis due to delayed refer-
ral to and therapy by a specialist and, subsequently, joint
destruction [1, 3, 5].
Moreover, RA is not a straightforward disease to diag-
nose due to its nature and epidemiology. Comparing the
number of RA patients in Austria and their general
practitioner (GP) counterparts makes it evident that an
Austrian primary care physician is confronted with 0.4
incident patients with RA per year (that is, dividing the
number of office-based GPs by the number of incident
RA patients in Austria). This number is in line with pub-
lished German studies [7, 8]. It is well established that
diagnostic accuracy is a function of frequency - and for
diseases as infrequent as RA a variety of approaches
exist that try to stimulate more rapid and integrated
cooperation between GPs and specialists [9–11].
All of these approaches promote a close interaction
between GPs and specialists to deepen the understand-
ing of RA and to establish easily applicable referral
criteria in suspected cases of RA.
The purpose of the present study was to assess
whether an improvement in the interdisciplinary patient
management of RA has the potential to simultaneously
improve health outcomes and reduce costs. Early identi-
fication and referral of RA patients to a rheumatologist
and rapid initiation of appropriate therapy is associated
with a better disease outcome. There is unequivocal
evidence that early treatment with the goal of achieving
remission has the potential to reduce impairments in
work productivity and daily activities [4, 12]. However,
to receive treatment, patients have to get in touch with
the right specialist first. Any retardation at this point in
the care continuum may lead to delayed initiation of
DMARD therapy resulting in radiographic joint damage
which would have been preventable [13]. Van der Linden
et al showed that RA patients, who were assessed within
12 weeks from symptom onset, were associated with less
joint destruction and a higher chance for remission com-
pared to patients with longer waiting times. [4].
Furthermore, diagnostic redundancies and physician
visits will be reduced which may lead to lower overall
costs.
Methods
Previously the British National Audit Office published a
report on two health economic models investigating the
impact of earlier diagnosis and treatment of RA patients
in England [14]. The effects evaluated included direct
costs, employment and the quality of life. We adopted
this approach for the present study to investigate
whether an improved referral pattern of suspected inci-
dent RA patients would be associated with better patient
care as well a reduced economic burden for the health
care system.
Taking into account country-specific differences in pa-
tient management, one of the aforementioned English
models served as the starting point of our analysis.
Patterns and probabilities of practice and patient flow
In a first and fundamental step, we modelled the differ-
ent ways, which lead patients with RA to the correct
diagnosis, and the relevant specialist, respectively. We
reconstructed the patient flow up to diagnosis in
Austria, from onset of symptoms, presentation to GP or
rheumatologist, GP referral to specialists, until, ultim-
ately, RA diagnosis.
Figure 1 depicts the different steps and measures taken
at the respective contact points. Expert interviews with
both GPs and rheumatologists served as the basis for the
decision tree [9].
After onset of symptoms, a patient has the option to
consult with his/her GP, to see a specialist, i.e. a rheuma-
tologist, directly, and to take advantage of the existing
hospital-based “Immediate Access Rheumatology Clinics”
[10] or office-based “Rapid Assessment Consultations
(RAC)” [11] (to date only in Vienna and Upper Austria;
not yet established nationwide). Data on practice patterns
and diagnostic steps taken at the different points of care
were taken from three published studies [10, 11, 15] and
verified with practicing rheumatologists [9].
In the Austrian health care system, it is certainly
intended that patients experiencing new symptoms of a
disease see their GP first, however, there is no formal
gate-keeping mechanism in place and patients are free
to see both an office-based as well as a specialist in a
clinic right away.
A GP who sees a patient with symptoms of RA is faced
with two courses of action: immediate referral to a
rheumatologist or watchful waiting, which most likely in-
cludes a blood analysis, the prescription of painkillers and
a follow-up appointment. Previously we could show [15]
that, on average, RA patients visit their GP 3 times before
referral. This, in turn, could affect not only costs associ-
ated with diagnosis, but also radiographic progression.
To compare the current situation to a new approach,
we first modelled the number of people with RA, diag-
nosed within 3 months of symptom onset, under current
practice [15] as well as the costs associated. We then
compared this situation against a reorganization, which
will be summarised as the rapid assessment consultation,
or RAC approach. The RAC aims at promoting fast
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diagnosis of early RA by fostering rapid identification
and referral. This service includes an initial examination
carried out by an experienced (office-based) rheumatolo-
gist. Regardless of the duration of symptoms, every pa-
tient is seen within 1 week (with or without referral), if
an inflammatory rheumatic disease is suspected or the
patient/referrer stresses the urgent need for a visit. Both
a tentative diagnosis and a proposal for further medical
care were given to the patients. In the case of a genuine
rheumatologic disorder, immediate therapy was initiated.
This approach has already been evaluated in Vienna
and with a cooperative of office-based rheumatolo-
gists in upper Austria, who established an immediate
access network offering brief initial assessments for
patients with musculoskeletal problems [10, 11]. A
description of the current or “traditional” patient
flow is depicted in Fig. 1.
We evaluated the impact of this change on the
number of RA patients diagnosed within a certain
timeframe as well as on the costs associated with
diagnosis. Table 1 shows the assumptions used in the
model.
Epidemiology
The incidence and prevalence of RA varies across popula-
tions and disease definitions. In North America and
Northern Europe, the annual incidence rate was estimated
at 20–50 cases per 100,000 population and the prevalence
at 0.5–1%. [16]. In 1994, the annual incidence was 36 per
100,000 in women and 14 per 100,000 in men; the preva-
lence was 0.8% of the adult population in the UK [17].
Table 2 summarises the demographic data [http://
www.statistik.at/web_de/statistiken/index.html] and inci-
dence rate estimates used in the model.
As there is no data on the epidemiology of RA in
Austria, we also used data from Wiles et al from 1999,
who estimate the yearly incidence of RA to be 24.5/
100,000 for men and 54/100,000 for women, as the basis
for the second scenario we modelled [18].
Statistical methods
To compare the current situation in Austria with
other scenarios, i.e. different parameterisations, we set
up a probabilistic simulation model. Parameters are on
the one hand probabilities concerning the disease
within the population as well as approximations of
various costs on the other hand, e.g. cost of treatment
(both GP and specialist). An important parameter is
the time a patient needs until he is receiving appropri-
ate treatment. To this end the time to treatment is di-
vided into five brackets, i.e. a certain probability
whether a patient receives treatment within 3 months,
Table 1 Patterns and probabilities of practice and patient flow
used in the model
Patterns of Practice and Patient Flow
Probability of seeing GP first after onset of symptoms 0.8 [15]
Number of GP visits in case of no diagnosis or no referral 3 [15]
Probabilities of Patient Flow
Probability of seeing GP first after onset of symptoms 0.8 [15]
Probability of seeing specialist first after onset of
symptomsa
0.13 [15]
a7% consulted an orthopedic surgeon or an internist first (= 0.07)
Fig. 1 Current patient pathway in Austria. Abbreviations: ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; FBC, full (=complete) blood
count; ALT, alanine transaminase; GGT, gamma-glutamyl transferase; UA, uric acid; Crea, creatinine; RF, rheumatoid factor; ACPA, antibodies against
citrullinated protein/peptide antigens
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6 months, 12 months, 24 months, and above respect-
ively is specified.
We assumed that patients are always in one of a finite
number of discrete health states, and all events are tran-
sitions from one state to another. Transitioning between
the health states is measured by the probabilities
described in detail above. Moreover, we included resource
use at each state. For each scenario, the total cost of the
diagnostic process is derived by multiplying volumes times
the unit cost of service provision.
The calculations and simulations have been conducted
using the statistical computing package R [19].
Results
Probability values of inflammatory arthritis, of diagnosis
after symptom onset by point in time and of correct
diagnosis by physician group
Probability values used in modelling were obtained from
literature reviews and expert opinion. Table 3 summarises
the parameters used as well as their sources [10, 15].
Our model includes all people who may have undiffer-
entiated arthritis (UA) (defined as people presenting with
symptoms similar to inflammatory arthritis which could
be inflammatory, but also non-inflammatory arthritis;
studies suggest that the incidence of UA is three times the
incidence of RA) [14, 20]. To fully capture the effects of a
closer cooperation between GPs and specialists, we had to
incorporate unintended effects on people with non-
inflammatory arthritis with similar symptoms presenting
to rheumatologists. We included the financial impact of
both inflammatory and non-inflammatory patient groups
and assessed diagnostic skill using data from a study by
Gärtner et al [10].
We designed a one-way sensitivity analysis consider-
ing various relevant variables, especially the relation-
ship between visits to a GP and the RAC approach,
the average amount of GP visits as well as the inci-
dent rate, i.e. the relationship between inflammatory
arthritis (IA) and UA within the population. It
allowed for an integration of the pricing of false-
positives and also supported a deeper general under-
standing of all parameters. Various scenarios have
been deployed to gain insight into cost trends. Based
on our base scenario and given a uniform distribution of
patients to either GP or the RAC approach, an increase of
average visits to the GP from 3 to 5 increased the total
costs by EUR 41,745. Changing the current practice
towards early referral of each and every patient with sus-
pected RA to a specialist has the potential to be truly cost-
saving, i.e. costs of EUR 51,041 can be saved.
Table 2 Epidemiology data used in the model
Epidemiology Reference
Austria’s mid-year male population, male, as per July 15, 2013 3,181,396 [http://www.statistik.at/web_de/statistiken/index.html].
RA: yearly incidence per 100,000 males 14 [17].
Austria’s mid-year female population, female, as per July 15, 2013 3,442,605 [http://www.statistik.at/web_de/statistiken/index.html].
RA: yearly incidence per 100,000 females 36 [17].
Probability of person presenting with symptoms of undifferentiated arthritis (UA) 0.00186 [14]
Table 3 Probability of Inflammatory Arthritis, of diagnosis after symptom onset by time point, of correct diagnosis by physician
group
P Reference
Probability of Inflammatory Arthritis
Probability of a patient presenting with IA (RA or other IA) 0.6438 [10]
Diagnostic Probabilities
Probability of RA diagnosis within 3 months 0.28 [15]
Probability of RA diagnosis within 4 to 6 months 0.16 [15].
Probability of RA diagnosis within 7 to 12 months 0.14 [15].
Probability of RA diagnosis within 13 to 24 months 0.17 [15]
Probabilities of Diagnostic Skill
Probability of correct diagnosis by GP 0.15 [15]
Probability of correct diagnosis by specialist 0.73 [15]
Probability of correct diagnosis by specialist 0.76 [10]
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Costing
Our analysis takes the perspective of a third party payer in
Austria, the Federation of Austrian Social Insurance Insti-
tutions (Hauptverband der Sozialversicherungsträger).
We compared the costs to the health system which are
incurred at each stage of the diagnostic process. The
following costs to the Federation of Austrian Social
Insurance Institutions are included in the model: GP
consultations; consultations by specialists, laboratory
tests, both those carried out by GPs prior to referral and
those carried out by specialists after referral (antibodies
against citrullinated protein/peptide antigens (ACPA), C-
reactive protein (CRP), tests for rheumatoid factor (RF),
erythrocyte sedimentation rate (ESR), complete blood
count (CBC), alanine transaminase gamma (ALT), gluta-
myltransferase (GGT), uric acid (UA), creatinine (Crea)).
No treatment or monitoring costs after diagnosis are
included in the present analysis.
Due to the perspective chosen for our analysis, indir-
ect costs such as loss of productivity and earnings due
to inability to work were not considered.
We adhered to the local national guidelines for health
economic analyses and therefore used the weighted aver-
age of tariffs of four Austrian sickness funds [21]. Table 4
details the costs used in the model and their sources.
The cost items included refer to the diagnostic param-
eters worked out by an expert panel of primary care
physicians and rheumatologists [10]. Figure 2 depicts the
steps of the patient flow used in the model as well as the
associated costs of each step. Yellow boxes indicate ac-
tivities taken at the GP level, while blue boxes contain
information on what happens at the specialist level.
Combining the parameters listed in Tables 2 and 3, we
estimate a total of 5294 people with undifferentiated
arthritis in Austria, of which 1765 suffer from RA.
Modelling for diagnostic accuracy, we found that 1200
of these patients are currently misdiagnosed in a primary
care setting. Inflammatory arthropathies are not straight-
forward to diagnose - even when consulting a specialist,
it is expected that 95 RA patients are not correctly diag-
nosed. However, there is a marked increase of diagnostic
accuracy at the specialist level (see Table 5).
In summary, our model shows that by adopting an
RAC approach and changing current practice towards
early referral of each and every patient with suspected
RA to a specialist has the potential to be not only cost-
effective, but cost-saving: EUR 100,188 could be saved
annually, by exclusively adopting the new integrated
approach. These savings accrue from a combination of
reduced GP visits and reduced diagnostic analyses taken
at the GP level.
Adopting the data on epidemiology suggested by Wiles
et al [18] mentioned above, we found that the number of
incident RA patients in Austria would rise to 2765 and
henceforth cost-savings of EUR 156,961 under the new
approach.
Discussion
By increasing diagnostic accuracy, patients will receive
disease-modifying anti-rheumatic drug (DMARD) treat-
ment earlier, which offers the potential to halt radio-
graphic damage. Joint destruction is in turn responsible
for patients’ inability to work and function, both in their
professional and private lives [13, 22, 23].
Huscher et al [24] showed that annual costs differ by
Health Assessment Questionnaire (HAQ) level – poor
functional status leads to higher direct costs. This proves
the notion that disease activity does indeed impact costs.
Radner et al [12] in their recent analysis found that the
same holds true for indirect costs treated at a tertiary
care centre in Austria.
We found that restructuring care for patients with sus-
pected RA by providing primary care physicians with clear
referral guidelines, a list of diagnostic measures which can
be performed before the first appointment with a specialist
[9] and specific contact points (eg Early Arthritis Clinics) is
less expensive and improves care at the same time.
In health economics, for any intervention to be con-
sidered cost-saving, the approach under consideration
must, at the same time, be less expensive and improve
clinical parameters. This is a rare occurrence: Cohen et
al [25] found that fewer than 1 in 5 interventions in
health and medicine that improve clinical care are also
cost-saving compared with usual care.
Moreover, although we have not modelled for indirect
cost, i.e. the impact of the intervention on patients’
ability to work, there is increasing evidence that this
cost category is reduced by way of prevented disease
progression as well. Furthermore, if early accurate
Table 4 Costs used in the model
Costs of Physician Visits Weighted Tariff
GP visit €27.83
Specialist visit €31.15
Costs of Diagnostic Procedures
Rheumatoid factor (RF) €3.66
C-reactive protein (CRP) €3.70
Erythrocyte sedimentation rate (ESR) €1.84
Antibodies against citrullinated protein/peptide
antigens (ACPA)
€14.33
Complete blood count (CBC) €4.08
Alanine Transaminase gamma (ALT) €2.22
Glutamyltransferase (GGT) €2.64
Uric acid (UA) €2.67
Creatinine (Crea) €2.58
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diagnosis leads to appropriate treatment, there should
be significant downstream cost savings in medication
and joint replacement surgeries [26, 27].
Overall, the assumptions made in the model are con-
servative, to minimize the risk of overstating the effects
of the parameters within the model.
The purpose of our study is not to blame Austrian
physicians in primary care for their lack of diagnostic
skill - far from it. The authors are convinced that col-
leagues in primary care act as important and trustworthy
counsellors who have known their patients - and very
often patients’ immediate families - for years. All too
often the burden of many chronic diseases rests on the
shoulders of these physicians. Yet, according to our esti-
mate, GPs see an average of 0.4 incident RA patients per
year - not only is RA hard to diagnose, it is also rare.
Our results show that by better directing the flow of
people with RA, simultaneous benefits may be reaped:
clinical and economic benefits.
As treatment guidelines [6] increasingly take the eco-
nomic impact of different therapeutic approaches into
account, it is important to allocate resources so that
health gain is maximised. Our analysis shows that re-
thinking the way patients have to go before receiving
their correct diagnosis has the potential to free resources
which can then be used to treat more patients or treat
Fig. 2 Costs incurred at each step of the patient pathway. Yellow boxes indicate GP activity, blue boxes indicate specialist activity. Abbreviations:
RAC, rapid assessment consultation
Table 5 Results of our health economic modelling of a
reconfiguration of patient flow of Austrian patients with
suspected RA
Patients (n)
All undifferentiated arthropathies 5,294
All RA (male and female) 1,765
Not (yet) diagnosed with RA by primary care physicians 1,200
Not (yet) diagnosed with RA by rheumatologists 95
Cost impact of existing referral pattern with suggested
modified approach
EUR
Cost savings GP visits 100,188
These annual savings accrue as the sum of reduced GP visits and reduced
diagnostic analyses taken at the GP level
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existing patients with innovative and, therefore, more
costly therapeutics.
An important strength of our analysis certainly per-
tains to the local data on practice patterns, diagnostic
accuracy and diagnostic measures we were able to use
thanks to previous work published [9–11, 15]. We relied
on first-hand information from both rheumatologists
and primary care physicians.
As said above, the role of a GP is quite extensive; he is
usually the first to see the patient with musculoskeletal
disorders and has to decide whether or not to refer a
patient to a rheumatologist. Moreover he has an import-
ant role in follow-up and surveillance. One of the main
reasons for a delay in seeing a specialist are long waiting
lists for rheumatologist appointments.
A limitation of our study is that the RAC approach,
which is the pre-condition of our reconfiguration, is not
yet available across the entire country. However, early
diagnosis and rapid initiation are important for patients’
outcome and much more likely when early arthritis
clinics and rapid assessment consultation are instituted.
Of note, it has been recently shown with office based
rheumatologists that overall workload and working
hours before and after implementation of RAC were the
same, however, with a different schedule due to regroup-
ing of patients. A patient with a suspicion of an inflam-
matory rheumatic disease is seen within 1 week; patients
in RAC without the need for specialist treatment can be
identified quickly and are given appropriate recommen-
dations for further care [11].
However, there are several other limitations the reader
should be aware of when interpreting the study at hand.
Firstly, we used a model, which per se is a depiction of
the Austrian situation and not necessarily reality. While
we think we are able to provide a fair estimate, our
analysis relies on the model being accurate. While we
modelled for the Austrian situation only and the local
situation might not necessarily be applicable to health
care systems in other countries, discussions with
colleagues practicing in other European countries lead
us to believe that the situations might be similar.
Another important limitation of our study is the
epidemiological data our analysis is based on - there is,
at this time, no nationwide registry. However, as this
kind of data is very important to all aspects of health
policy and priority setting in health care, we strongly
advocate to support efforts geared at improving this situ-
ation. Moreover, this would greatly enhance transpar-
ency in health care decision-making.
Conclusions
In conclusion, initiation of care by a rheumatologist early
on in the disease offers the potential for dramatically im-
proving clinical outcomes in patients with RA [13, 23].
Our work further underscores the importance of RAC,
also in remote settings, as early diagnosis is crucial for
patients’ prognosis. Lastly there is the potential of eco-
nomic benefits.
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